Dinuclear metal complexes have emerged as a promising class of anticancer compounds with the ability to cross-link biomolecular targets. Here, we describe two novel series of phosphine-linked dinuclear ruthenium(II) p-cymene and gold(I) complexes, in which the length of the connecting poly(ethylene glycol) chain has been systematically modified. The impact of the multinuclearity, lipophilicity, and linker length on the antiproliferative activity of the compounds on tumorigenic (A2780 and A2780cisR) and nontumorigenic (HEK-293) cell lines was assessed. The dinuclear ruthenium-(II) complexes were considerably more cytotoxic than their mononuclear counterparts, and a correlation between the lipophilicity of the linker and the cytotoxicity was observed, whereas the cytotoxicity of the gold(I) series is independent of these factors.
■ INTRODUCTION
The clinical success of cisplatin resulted in considerable efforts being directed toward the development of other platinumbased therapeutics. 1 However, the need to overcome the adverse side effects and intrinsic or acquired resistance to these compounds led to the investigation of alternative metals for their therapeutic potential. 2 Ruthenium(III) complexes imidazolium [trans-tetrachloro(1H-imidazole)(S-dimethyl sulfoxide)ruthenate(III)] 3 and indazolium trans-[tetrachlorobis(1Hindazole)ruthanate(III)] (KP1019) 4−6 and its sodium analogue (NKP1339) 7 have completed phase I and I/II clinical trials. Ruthenium (II) organometallic compounds have also attracted attention because they exhibit a number of promising pharmacological properties. 8−10 For example, the so-called RAPTA complexes (Figure 1 ), 11 of the general formula [Ru(η 6arene)(PTA)X 2 ] (PTA = 1,3,5-triaza-7-phosphaadamantane), and the RAED complexes, [Ru(η 6 -arene)(en)Cl] + (en = ethylenediamine), 12 have been particularly well studied for their anticancer properties. RAPTA-C 13 and RAED-C, 14 (where C = p-cymene) along with their derivatives exhibit an array of promising in vitro and in vivo properties. 9,12,13,15−19 Interestingly, crystallographic studies on the nucleosome core particle have shown that the choice of ligand strongly influences the biomolecular target of ruthenium(II) arene complexes with RAED-C preferentially binding to DNA and RAPTA-C binding to the histone proteins. 20, 21 Mononuclear gold(I) phosphine complexes have been evaluated for anticancer properties and exhibit promising activity. 22−25 Auranofin (1-thio-β-D-glucopyranose-2,3,4,6-tetraacetato-S)(triethylphosphine)gold(I) ( Figure  1 ), which is used clinically for the treatment of rheumatoid arthritis, 25, 26 is currently being repositioned as an anticancer drug. 27−32 Similar to RAPTA complexes, 33, 34 auranofin preferentially binds to cysteine-rich proteins such as thioredoxin reductase (TrX). 35−37 Multinuclearity, i.e., covalently connecting two or more metal centers via an appropriate linker, emerged as an approach to introducing new modes of action to overcome resistance in chemoresistant cancers. 38 The trinuclear platinum compound [{trans-PtCl(NH 3 ) 2 } 2 -μ-(trans-Pt(NH 3 ) 2 {H 2 N(CH 2 ) 6 -NH 2 } 2 ] 4+ ] (BBR3464; Figure 1 ) can overcome cisplatin resistance, and it exhibits a profile of antitumor efficacy distinct from that of cisplatin in a number of preclinical models. 39 However, despite successfully passing phase I clinical trials, BBR3464 failed a phase II evaluation, with only a minor response observed in small lung cancer and gastric/gastroesophageal adenocarcinoma. 40, 41 A growing number of multinuclear ruthenium (II) and gold(I) complexes have also been reported. 38 Interest in homobimetallic ruthenium (II) complexes has focused on the structure−reactivity investigations and the use of bioactive bridging ligands such as thiosemicarbazones. 42, 43 The influence of the spacer length on in vitro anticancer activity has previously been explored using bis(pyridinone)alkane linkers (η 6 -p-cymene)Ru(O,O-C 6 H 5 O 2 N(CH 2 ) n NC 6 H 5 O 2 -O,O)Ru-(η 6 -p-cymene) (RU1, with n = 3, 6, 12; Figure 1 ), where the cytotoxicity correlates to the lipophilicity, which increases with increasing linker length. 44 Both proteins and DNA were identified as possible targets for the dinuclear ruthenium (II) complexes, which hydrolyze rapidly to form active diaqua species. 45 Interestingly, the cytotoxicity of the complex with the longest bridging ligand was attributed to the ability of the complex to form both DNA−DNA and DNA−protein crosslinks. 46 A RAED-type binuclear complex, [(Ru(η 6 -biphenyl)-Cl(en)) 2 (CH 2 ) 6 ] 2+ , similarly bearing an alkyl linker, has been shown to form interstrand DNA cross-links. 47 Flexible alkyl spacers used in acylpyrazolonato-bridged ruthenium(II) com-plexes led to complexes with a higher cytotoxicity than those of related compounds with rigid phenyl spacers. 48 Attempts were made to investigate poly(ethylene glycol) (PEG) linkers; however, the bis(nicotinate)/bis(isonicotinate) ligands were unstable in solution. 49 Homobinuclear ruthenium (II) conformations. The dinuclear complexes are considerably more cytotoxic than the monomers but did not display cancer cell selectivity. 50 Consequently, a strategy was subsequently developed to generate dinuclear ruthenium (II) complexes directly in cancer cells. 51 Significant efforts have also been devoted to the development of diphosphinegold(I) complexes. 52−58 However, little attention has been paid to the nature of the linker in homobinuclear gold(I) complexes. A series of [(AuCl) 2 (Ph 2 P-(CH 2 ) n PPh 2 )] (where n = 1−6) complexes were prepared and evaluated in vitro against murine B16 melanoma cells (AU1; Figure 1 ). The cytotoxicity initially decreases with the linker length, n = 1 (6 μM) and 2 (8 μM), up to n = 3, where a plateau is reached (n = 3−6, IC 50 = 2−3 μM). 59 Alkyl linkers were also assessed in phosphine-bridged dinuclear gold(I) alkynyl complexes linked via (CH 2 ) n (where n = 1 and 4) groups. 60 More recently, investigations into the lipophilicity have included the exchange of hydrophobic PPh 3 ligands with more lipophilic PEt 3 ligands in dinuclear phosphinegold(I) sulfanylcarboxylate complexes resulting in lower IC 50 values against selected cell lines. 61 Other investigations include the optimization of TrX inhibition bridging bis(N-heterocyclic carbene) ligands, 62−64 alkylnyl ligands, 60,65−67 and thiocarbonates. 68, 69 Because the use of alkyl chains produced a general dependence between the linker length and cytotoxicity, correlating with increasing lipophilicity, we decided to evaluate the effect of PEG chains. Herein, we report the synthesis, structural characterization, and antiproliferative activity of two series of dinuclear complexes based on ruthenium(II) and gold(I) systems. The diruthenium(II) and digold(I) centers are linked via PEG chains of varying length, while the basic structures of the parent drugs RAPTA-C and auranofin are maintained. This strategy allows the influence of the linker length on the cytotoxicity to be studied and compared to their monometallic precursors.
■ RESULTS AND DISCUSSION
Two series of homobinuclear ruthenium(II) p-cymene, 1b−7b, and gold(I), 1d−7d, derivatives were prepared using the routes shown in Scheme 1. Universal diphosphine ligands 1a−7a were synthesized via an esterification reaction between 4-(diphenylphosphanyl)benzoic acid and the appropriate ethylene glycol in the presence of N-ethyl-N′-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDCI), a coupling agent, and 4-(dimethylamino)pyridine (DMAP), a basic catalyst. Ligands 1a−7a were isolated by chromatographic purification in moderate yields (36−64%).
The diruthenium(II) p-cymene complexes 1b−7b were obtained in high yield (96−98%) in a single step from the reaction of the appropriate ligands 1a−7a with the [Ru(η 6 -pcymene)Cl 2 ] 2 dimer, under inert conditions in dry dichloromethane (CH 2 Cl 2 ; Scheme 1). The binuclear gold(I) β-Dthioglucosetetraacetate complexes 1d−7d were prepared by following a two-step strategy (Scheme 1). The intermediate binuclear gold(I) chloride complexes, 1c−7c, were obtained in good yield (95−98%) from direct reaction of the appropriate diphosphine ligands 1a−7a with Au I Cl(tht) (tht = tetrahydrothiophene), freshly prepared following an adapted literature procedure. 70, 71 The subsequent reaction of 1c−7c with the β-Dthioglucosetetraacetate ligand under basic conditions (K 2 CO 3 ) in acetone or ethanol (EtOH)/water (H 2 O) affords the desired gold(I) complexes 1d−7d in good yield (84−96%). 71, 72 Mononuclear complexes were also prepared to provide a structure−activity comparison between the binuclear complexes and the parent drugs, RAPTA-C and auranofin. The mononuclear ruthenium(II) p-cymene (8b and 9b) and gold(I) (8d and 9d) complexes, containing 4-(diphenylphosphanyl)benzoic acid and triphenylphosphine ligands, were prepared from the direct reaction of phosphines with the [Ru(η 6 -pcymene)Cl 2 ] 2 dimer and Au I Cl(tht) precursors, respectively (Scheme 2).
All compounds were characterized by 1 H, 31 P, and 13 C NMR spectroscopy, mass spectrometry (MS), and elemental analysis. In the 31 P NMR spectra, the phosphine ligands 1a−7a produce a singlet between −4.99 and −5.08 ppm. In the binuclear complexes, the peaks shift to higher frequencies, with singlet resonances observed at 24 Coordination of the ligands to the metal ions is denoted by the peaks corresponding to the carbon atoms directly connected to the phosphorus center shifting to lower frequencies (with increased 1 J C,P coupling constants) in the 13 C NMR spectra. In the diruthenium(II) p-cymene complexes 1b−7b, a shift of Δδ C ≈ 4.9 ppm and coupling of Δ 1 J C,P ≈ 28 Hz were observed for the two C−P carbon atoms on the functionalized ring and Δδ C ≈ 3 ppm and Δ 1 J C,P ≈ 34 Hz for the peaks corresponding to the four C−P carbon atoms on the phenyl rings. An analogous effect was observed for the digold(I) complexes, for 1c−7c, there is a shift of Δδ C ≈ 9.6 ppm and a coupling of Δ 1 J C,P ≈ 45 Hz, corresponding to the two C−P carbon atoms on the functionalized ring and a shift of Δδ C ≈ 8.5 ppm and Δ 1 J C,P ≈ 52 Hz representing the four C−P carbon atoms on the phenyl rings. A comparable, but slightly less pronounced, effect is observed in the 13 C NMR spectra of 1d−7d, and in the mononuclear complexes, similar changes are also observed.
The impact of increasing PEG chain length on the electronic environment of the metal centers is negligible, with all coupling constants and 31 P peaks remaining consistently similar throughout the series.
The most abundant peaks observed in the electrospray ionization MS (ESI-MS) spectra may be assigned to [ The solid-state structures of 9b and 9c were established by single-crystal X-ray diffraction analysis, confirming the expected molecular structures. Single crystals of 9b were grown via the slow evaporation of chloroform from a concentrated solution ( Figure 2 ). 9b contains four independent molecules in each asymmetric unit ( Figure S1 ) compared to the two found for RAPTA-C. 73 Key bond parameters are compared with those of RAPTA-C (Table 1 ) and, overall, the arrangement around the ruthenium(II) center is remarkably similar to that of 9b, adopting the familiar half-sandwich three-legged piano-stool geometry. The mean Ru−η 6 distance is longer in 9b (1.706− 1.723 Å) than in RAPTA-C (1.692−1.701 Å), and the same trend is observed for the Ru−P bond lengths [9b, 2.363(2)− 2.3691(19) Å; RAPTA-C, 2.296(2)−2.298(3) Å]. The average Ru−Cl bond lengths and Cl−Ru−Cl angles are similar for both complexes; however, a difference is observed in the average P− Ru−Cl angles, with those in 9b (88.78−89.91°) being consistently larger than those in RAPTA-C (84.04−87.25°). In the crystal of 9b, intermolecular hydrogen bonds between the carboxylic acid groups are observed, leading to the formation of homodimeric assemblies ( Figure S2 ).
The slow diffusion of tetrahydrofuran (THF) into a saturated solution of 9c in CDCl 3 afforded crystals suitable for X-ray diffraction analysis ( Figure 3 ). The bond parameters around the gold(I) center in 9c are presented in Table 2 and compared with those of auranofin. 74 The Au−P bond distance in 9c [2.233(9) Å] is comparable to the value observed in auranofin a In the crystal of RAPTA-C, there are two independent molecules in the asymmetric unit. b In 9b, there are four independent complexes in the asymmetric unit. Figure S3 ). The lipophilicity has previously been correlated to increasing cytotoxicity in dinuclear ruthenium(II) complexes (RU1; Figure 1 ). 45 Consequently, the partition coefficients (log P) of PEG chains and alkyl chains were calculated. 75, 76 As expected, the lipophilicity of the alkanes increases with increasing chain length (Chart 1), a trend that is transferred to diruthenium complexes bearing alkyl linkers of the structure (η 6 = 3, 6, and 12) . 45 In contrast, PEG chains have limited lipophilicity, with the hydrophobicity increasing with the chain length up to hexakis(ethylene glycol), where a plateau is reached. According to calculations, octakis(ethylene glycol) is the most lipophilic with a log P value of −0.63, and longer PEG chains become increasingly hydrophilic. The plateau, consisting of PEG chains 6−9, have similar log P values in the range −0.62 to −0.67. Log P octanol/H 2 O values were determined experimentally for 1b−7b and 1d−7d using the shake-flask method ( Table 1) . 77 The log P values reside in the lipophilic range for both series. Digold(I) β-D-thioglucosetetraacetate complexes 1d−7d are more hydrophilic than their ruthenium counterparts 1b−7b because of the presence of two β-D-thioglucosetetraacetate ligands. For the shorter chain lengths, 1b−4b and 1d−3d, the lipophilicity was shown to increase with increasing chain length for both series. However, for complexes bearing longer chain lengths, 5b−7b and 5d−7b, the log P values remain essentially constant despite increasing chain length, values of which are 1.4−1.5 and 0.3−0.4, respectively.
The cytotoxicity of the 1a−7a ligands and ruthenium(II) pcymene 1b−9b and gold(I) β-D-thioglucosetetraacetate 1d−9d complexes was assessed against human ovarian carcinoma cell lines, A2780 and A2780cisR, with the latter having acquired resistance to cisplatin and nontumoral human embryonic kidney (HEK-293) cells using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay ( Table 3 ). The cytotoxicities of 4-(diphenylphosphanyl)benzoic acid, triphenylphosphine, auranofin, cisplatin, and RAPTA-C were evaluated for comparison purposes. Elemental analysis indicates that CH 2 Cl 2 and CDCl 3 are present in some compounds; therefore, their cytotoxicities were evaluated at IC 50 concentration, and they were found to be inactive.
All compounds were predissolved in dimethyl sulfoxide (DMSO), and their stability in this solvent was confirmed via 1 H and 31 P NMR spectroscopy (Figures S4−S7), before being immediately diluted into the appropriate cell culture medium. Further stability studies under pseudocell culture conditions of 100 mM NaCl in H 2 O and 5% DMSO were conducted on 2d, 4d, and 6d complexes over 72 h. The stability was monitored via ESI-MS(+) (Figures S8−S10), and all complexes showed good stability under these conditions.
The original RAPTA series possess low cytotoxicities with IC 50 values of >200 μM against a range of cell lines. 11 As discussed above, the structures of 9b and RAPTA-C are comparable, and the similarities are reflected in their cytotoxicities, with IC 50 values >200 μM determined against all tested cell lines. However, the mononuclear ruthenium(II) complex 8b, bearing a hydrophobic triphenylphosphine ligand, is considerably more cytotoxic than 9b, with an IC 50 of 42 ± 1 μM. A similar trend is present with 8d and 9d, with 9d being ca. 14-fold more cytotoxic than 8d. The free ligands triphenylphosphine and 4-(diphenylphosphanyl)benzoic acid also present respective IC 50 values of 85 ± 7 and >200 μM against the A2780 cell line; the differences may be attributed to the differences in the lipophilicity. However, the impact of global charge may be of influence.
The diphosphine ligands 1a−7a are inactive at concentrations of up to 500 μM on the three cell lines. The dinuclear complexes 1b−7b and 1d−7d are considerably more cytotoxic than the mononuclear complexes 9b and 9d against all cell lines. The complexes containing the mono(ethylene glycol) linker (1b and 1d) are considerably less cytotoxic than the complexes with longer linkers (2b−7b and 2d−7d). In contrast, in a series of diruthenium(II) p-cymene complexes with bridging bis(nicotinate)/bis(isonicotinate) ligands, only the complex with the shortest mono(ethylene glycol) linker possessed moderate activity against a range of cell lines including the human melanoma (518A2) cell line (IC 50 = 53 ± 1 μM). 49 The diruthenium(II) p-cymene complexes 2b−7b exhibit IC 50 values in the low micromolar range against the A2780 cell line. The cytotoxicity toward the cisplatin-resistant cell line (A2780cisR) remains in the low micromolar range, with up to 2-fold loss in cytotoxicity compared to the A2780 cisplatinsensitive cell line for 3b and 5b. No selectivity was observed toward the cancer cell lines, with the values obtained for the nontumorigenic HEK-293 cell line being similar in magnitude. The cytotoxicities of these dinuclear complexes are comparable to those of previously investigated series including the series of rigid RAPTA-type dinuclear complexes, linked via the functionalization of the η 6 -arene, where the most active complex has an IC 50 of 3.7 ± 0.6 μM against the A2780 cell line. 50 The relationship between the linker length and cytotoxicity on the A2780 cell line shows increasing cytotoxicity with increasing linker length between 3b and 5b, which correlates with the increasing lipophilicity of the linkers. However, 2b with the bis(ethylene glycol) linker is ca. 2-fold more cytotoxic than 3b. The lipophilicity is essentially constant for compounds 6b and 7b, with the IC 50 values being 7.3 ± 0.3 and 11.6 ± 0.9 μM, respectively.
The digold(I) β-D-thioglucosetetraacetate complexes 1d−7d are highly cytotoxic on all three tested cell lines, with IC 50 values in the low micromolar range. Compounds 2d−7d are highly cytotoxic against A2780 cells (with IC 50 values between 0.17 and 0.25 μM), while being significantly less active, up to 8fold, on the cisplatin-resistant A2780cisR cell line. The IC 50 values of 1d−7d on nontumorigenic HEK-293 cells are very similar to those on A2780cisR cells. Interestingly, no major differences are observed between the activities of the digold(I) complexes 2d−7d and the mononuclear complex 8d, containing the hydrophobic PPh 3 ligand, whereas 9d, with t h e m o r e h y d r o p h i l i c p h o s p h i n e l i g a n d , i . e . , (C 6 H 5 ) 2 PC 6 H 4 CO 2 H, is ca. 35-fold less cytotoxic in A2780 cells and ca. 10-fold less cytotoxic in A2780cisR and HEK-293 cells. With the exception of complexes 1d and 9d, the activities are in the same order as those of auranofin.
Complexes 2d−7d display a narrow range of IC 50 values between 0.17 ± 0.01 and 0.25 ± 0.02 μM and, thus, there is no discernible correlation with the linker length and associated lipophilicity. However, the series is significantly more cytotoxic than [(AuCl) 2 (Ph 2 P-(CH 2 ) n PPh 2 )] (where n = 1−6), in which the most active complexes (n = 3, 5, and 6) have IC 50 values of ca. 2 μM, again murine B16 melanoma cells. 59 A trend was observed in this alkyl-linked series with 3-fold (n = 1) and 4fold (n = 2) higher cytotoxicities for the more lipophilic complexes. 59 The series is also significantly more cytotoxic than the phosphine-bridged dinuclear gold(I) alkynyl complexes bearing alkyl linkers, where no correlation was observed between the cytotoxicity and linker length. 60 
■ CONCLUDING REMARKS
The synthesis of two series of homobinuclear RAPTA-like ruthenium(II) p-cymene complexes 1b−7b and auranofin-like gold(I) complexes 1d−7d, linked via diphosphine-modified PEG chains of varying length, was successfully achieved. The antiproliferative activity of these compounds was determined against tumorigenic and nontumorigenic cell lines, and a distinct increase the cytotoxicity was observed for both series compared to the mononuclear precursors 9b and 9d. There is a correlation between the lipophilicity and cytotoxicity of the diruthenium(II) complexes, which reaches a plateau where the lipophilicity no longer increases with the length of the PEG chain, i.e., when n = 6. In contrast, the cytotoxicities of all of the digold(I) complexes lie within a narrow range and are not readily correlated to the linker length and associated lipophilicity.
■ EXPERIMENTAL SECTION Materials. RuCl 3 ·3H 2 O was purchased from Precious Metals Online. All other chemical reagents were purchased from Aldrich, Alfa Aesar, Acros, and TCI Chemicals and used without further purification. [Ru(η 6 -p-cymene)Cl 2 ] 2 78 and AuCl(tht) 70, 71 were prepared following literature procedures. CH 2 Cl 2 was dried and degassed using a PureSolv solvent purification system (Innovative Technology Inc.). Thin-layer chromatography was conducted on Merck 60 F254 
a Values are given as the mean ± standard deviation (μM). (2) K] using Mo Kα radiation on a Bruker APEX II CCD diffractometer equipped with a Kappa geometry goniometer. The data sets were reduced by EvalCCD 79 and then corrected for absorption. 80 The solutions and refinements were performed by SHELX. 81, 82 The crystal structures were refined using full-matrix least squares based on F 2 , with all non-hydrogen atoms anisotropically defined. Hydrogen atoms were placed in calculated positions by means of the "riding" model. The log P values of PEG and alkyl linker compounds were predicted using the Virtual Computational Chemistry Lab (VCCLAB). 75, 76 The experimental log P octanol/H 2 O values were determined using the shake-flask method, 77 and the absorbance of each fraction was recorded using a SpectroMax M5e multimode microplate reader (using Sof tMax Pro software, version 6.2.2). The absorbance of the MTT assay 96-well plates was recorded using a SpectroMax M5e multimode microplate reader (using Sof tMax Pro software, version 6.2.2).
Inorganic Chemistry
Synthesis. General Procedure for the Synthesis of the Diphosphine Ligands 1a−7a. 4-(Diphenylphosphanyl)benzoic acid (2.2 equiv) and EDCI (2.4 equiv) were dissolved in CH 2 Cl 2 (50 mL) and stirred under N 2 at room temperature (RT) for 15 min. The appropriate ethylene glycol (1.0 equiv) and DMAP (0.4 equiv) were added, and the mixture was further stirred for 24 h at RT. The reaction mixture was washed with H 2 O (150 mL), and the aqueous phase was reextracted with CH 2 Cl 2 (2 × 100 mL). The organic phase was washed with brine (150 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The treated product was purified by flash column chromatography using an adapted elution system of hexanes/ethyl acetate or CH 2 Cl 2 /methanol. The product was recovered as a colorless viscous solid.
Compound 1a. According to the general procedure, 4-(diphenylphosphanyl)benzoic acid (0.900 g, 2.938 mmol, 2.2 equiv), mono(ethylene glycol) (0.075 mL, 1.345 mmol, 1 equiv), EDCI (0.614 g, 3.203 mmol, 2.4 equiv), and DMAP (0.065 g, 0.532 mmol, 0.4 equiv) were stirred for 24 h in CH 2 3 3 Compound 7a. According to the general procedure, 4-(diphenylphosphanyl)benzoic acid (0.800 g, 2.612 mmol, 2.2 equiv), octakis(ethylene glycol) (0.440 g, 1.188 mmol, 1 equiv), EDCI (0.546 g, 2.848 mmol, 2.4 equiv), and DMAP (0.058 g, 0.475 mmol, 0.4 equiv) were stirred for 24 h in CH 2 Cl 2 (50 mL). Yield: 0.499 g, 0.527 mmol, 45%. Elem anal. Calcd for C 54 H 60 O 11 Compound 2b. According to the general procedure, [Ru(η 6 -pcymene)Cl] 2 Cl 2 (0.49 g, 0.808 mmol, 1 equiv), 2a (0.55 g, 0.808 mmol, 1 equiv), and CH 2 Cl 2 (12 mL) were stirred for 42 h at RT. The product was isolated as a dark-red solid. Yield: 1.03 g, 0.791 mmol, 98%. Elem anal. Calcd for C 62 H 64 Compound 5b. According to the general procedure, [Ru(η 6 -pcymene)Cl] 2 Cl 2 (0.16 g, 0.269 mmol, 1 equiv), 5a (0.22 g, 0.269 mmol, 1 equiv), and CH 2 Cl 2 (12 mL) were stirred for 42 h at RT. The product was isolated as a red solid. Yield: 0.38 g, 0.263 mmol, 98%. Elem anal. Calcd for C 68 H 76 Compound 6b. According to the general procedure, [Ru(η 6 -pcymene)Cl] 2 Cl 2 (0.16 g, 0.261 mmol, 1 equiv), 6a (0.22 g, 0.261 mmol, 1 equiv), and CH 2 Cl 2 (12 mL) were stirred for 42 h at RT. The product was isolated as a red solid. Yield: 0.38 g, 0.256 mmol, 98%. Elem anal. Calcd for C 70 H 80 Cl 4 Compound 8b. According to the general procedure, [Ru(η 6 -pcymene)Cl] 2 Cl 2 (0.30 g, 0.490 mmol, 1 equiv), PPh 3 (0.26 g, 0.979 mmol, 2 equiv), and CH 2 Cl 2 (12 mL) were stirred for 42 h at RT. The product was isolated as a dark-red solid. Yield: 0.54 g, 0.950 mmol, 9. Elem anal. Calcd for C 28 H 29 General Procedure for the Synthesis of the Digold Intermediates 1c−7c. The appropriate ligand,1a−7a (1 equiv), dissolved in dry CH 2 Cl 2 (15 mL), was added to a solution of AuCl(tht) (2 equiv) in dry CH 2 Cl 2 (10 mL) at 0°C under N 2 . The reaction mixture was stirred at RT for 6 h, and the reaction evolution was monitored by 1 H and 31 P NMR (CDCl 3 ). The reaction mixture was concentrated under reduced pressure, and the product was washed with hexane (5 × 25 mL) and resolubilized in CH 2 Cl 2 (50 mL), before being concentrated and further dried under high vacuum. The product was isolated as a white solid and stored at −20°C in the dark.
Compound 1c. According to the general procedure, AuCl(tht) (0.188 g, 0.588 mmol, 2 equiv), 1a (0.188 g, 0.294 mmol, 1 equiv), and CH 2 13 13 13 Compound 5c. According to the general procedure, AuCl(tht) (0.162 g,0.507 mmol, 2 equiv), 5a (0.206 g, 0.253 mmol, 1 equiv), and CH 2 Cl 2 (35 mL), were stirred for 6 h at RT. The product was isolated as a white solid. Yield: 0.308 g, 0.241 mmol, 95%. Elem anal. Calcd for C 48 H 48 Au 2 Compound 7c. According to the general procedure, AuCl(tht) (0.230 g, 0.720 mmol, 2 equiv), 7a (0.340 g, 0.359 mmol, 1 equiv), and CH 2 Cl 2 (35 mL) were stirred for 6 h at RT. The product was isolated as a white solid. Yield: 0.485 g, 0.344 mmol, 96%. Elem anal. Inorg. Chem. 2017, 56, 9617−9633 2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. 83 Cells were seeded in flat-bottomed 96-well plates as a suspension in a prepared medium (100 μL aliquots and approximately 4300 cells/ well) and preincubated for 24 h. Stock solutions of compounds were prepared in DMSO and were rapidly diluted in a medium. The solutions were sequentially diluted to give a final DMSO concentration of 0.5% and a final compound concentration range (0−500 μM).
Cisplatin was tested as a positive control (0−100 μM). The compounds were added to the preincubated 96-well plates in 100 μL aliquots, and the plates were incubated for 72 h. MTT (20 μL, 5 mg/mL in Dulbecco's phosphate buffered saline) was added to the cells, and the plates were incubated for a further 4 h. The culture medium was aspirated, and the purple formazan crystals, formed by the mitochondrial dehydrogenase activity of vital cells, were dissolved in DMSO (100 μL/well). The absorbance of the resulting solutions, directly proportional to the number of surviving cells, was quantified at 590 nm using a microplate reader. The percentage of surviving cells was calculated from the absorbance of wells corresponding to the untreated control cells. The reported IC 50 values ( 
